Point Of Care Hemoglobin Device Used In A Multicenter Study Of The Initiation Of Four Dosing Regimens Of ERYTHROPOIETIN Or The Treatment of Anemia Of Chronic Kidney Disease (CKD)

A global healthcare leader that pursues innovative solutions in the therapeutic areas of immunology, oncology and nephrology.

The primary objective of this study was to compare change in hemoglobin (Hb) from Baseline to the end of the study between the Q2W (every 2 weeks) and the Q4W (every 4 weeks) dosing regimens in subjects with anemia of CKD initiated on ERYTHROPOIETIN. The hypothesis tested was that the Q4W dosing regimens were not inferior to the Q2W dosing regimen in mean change in Hb between Baseline and the average of the last 4 weeks of the study. The secondary objectives of this study were to evaluate the Hb response, time to Hb response, packed red blood cell (pRBC) transfusions, and ERYTHROPOIETIN dose.